"peficitinib" meaning in All languages combined

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "peficitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2168:",
          "text": "Peficitinib, a pan-JAK inhibitor, is approved in Japan, Republic of Korea, and Taiwan for the treatment of RA in patients with an incomplete response to csDMARDs (19, 20). Tofacitinib, baricitinib, and peficitinib have shown clinical, functional, and radiographic efficacy, after failure of a csDMARD, prior to treatment with a bDMARD, or after treatment with a bDMARD.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Janus kinase inhibitors, used for the treatment of rheumatoid arthritis."
      ],
      "id": "en-peficitinib-en-noun-jZrHwNAf",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "rheumatoid arthritis",
          "rheumatoid arthritis"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of rheumatoid arthritis."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "peficitinib"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "peficitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2168:",
          "text": "Peficitinib, a pan-JAK inhibitor, is approved in Japan, Republic of Korea, and Taiwan for the treatment of RA in patients with an incomplete response to csDMARDs (19, 20). Tofacitinib, baricitinib, and peficitinib have shown clinical, functional, and radiographic efficacy, after failure of a csDMARD, prior to treatment with a bDMARD, or after treatment with a bDMARD.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Janus kinase inhibitors, used for the treatment of rheumatoid arthritis."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "rheumatoid arthritis",
          "rheumatoid arthritis"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of rheumatoid arthritis."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "peficitinib"
}